Current topics in microbiology and immunology最新文献

筛选
英文 中文
Viral Entry. 病毒进入。
3区 医学
Current topics in microbiology and immunology Pub Date : 2025-05-15 DOI: 10.1007/82_2025_300
Samantha Hardy, Crystal B Chhan, Amelia R Davis, Andrew T McGuire
{"title":"Viral Entry.","authors":"Samantha Hardy, Crystal B Chhan, Amelia R Davis, Andrew T McGuire","doi":"10.1007/82_2025_300","DOIUrl":"https://doi.org/10.1007/82_2025_300","url":null,"abstract":"<p><p>Epstein-Barr virus chiefly infects B cells and epithelial cells but is capable of infecting other cell types in the human host. Host cell entry is a complex process mediated by several viral glycoproteins that define tropism and mediate membrane fusion. This chapter will review what is known about the function of viral glycoproteins in the entry process, explore the nature of interactions between viral glycoproteins and host cell receptors, and highlight gaps in knowledge about the entry process that remain to be filled.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143978603","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges. 登革热困境:导航交叉反应性和免疫挑战。
3区 医学
Current topics in microbiology and immunology Pub Date : 2025-05-14 DOI: 10.1007/82_2025_294
Cristina R de Barros Cardoso, Thiago Cerqueira-Silva, Manoel Barral-Netto, Viviane S Boaventura
{"title":"Dengue Dilemma: Navigating Cross-Reactivity and Immune Challenges.","authors":"Cristina R de Barros Cardoso, Thiago Cerqueira-Silva, Manoel Barral-Netto, Viviane S Boaventura","doi":"10.1007/82_2025_294","DOIUrl":"https://doi.org/10.1007/82_2025_294","url":null,"abstract":"<p><p>This chapter examines the immunological mechanisms underlying the cross-reactivity and immune enhancement in dengue and how they influence the clinical outcomes. The four DENV serotypes (DENV-1 to DENV-4) share high genetic and antigenic similarity, leading to antibodies and T cells that can recognize multiple serotypes. While this cross-reactive immunity can confer partial or transient protection, it can also result in antibody-dependent enhancement (ADE), wherein non-neutralizing antibodies facilitate viral entry into immune cells, increasing the likelihood of severe disease in secondary infections and in infants carrying maternal anti-DENV antibodies. Furthermore, cross-reactivity with other flaviviruses, such as ZIKV, complicates serological diagnosis by producing false-positive results and uncertain prior exposure histories. These complexities extend to vaccine design, which must induce effective immunity against all four DENV serotypes while minimizing ADE risk. Epidemiological studies confirm that secondary infections, especially when antibody levels have waned, carry an elevated risk of severe clinical manifestations. However, the timing between infections and the specific serotype involved can modulate these outcomes. A thorough understanding of cross-reactivity and immune enhancement is therefore pivotal for advancing diagnostic accuracy, guiding patient care, and informing vaccine strategies and public health policies to better control dengue globally.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143982155","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19. 更正:COVID-19之前针对细菌和病毒疾病的多克隆抗体治疗简史。
3区 医学
Current topics in microbiology and immunology Pub Date : 2025-05-10 DOI: 10.1007/82_2025_295
Nigel Paneth, Madison Walsh, Breanna Kornatowski, Arturo Casadevall
{"title":"Correction to: A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19.","authors":"Nigel Paneth, Madison Walsh, Breanna Kornatowski, Arturo Casadevall","doi":"10.1007/82_2025_295","DOIUrl":"https://doi.org/10.1007/82_2025_295","url":null,"abstract":"","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-05-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143984985","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dengue: Historical Aspects. 登革热:历史方面。
3区 医学
Current topics in microbiology and immunology Pub Date : 2025-04-30 DOI: 10.1007/82_2025_289
Myrna Cristina Bonaldo, Samuel Goldenberg, Ricardo Galler, Claudia Nunes Duarte Dos Santos
{"title":"Dengue: Historical Aspects.","authors":"Myrna Cristina Bonaldo, Samuel Goldenberg, Ricardo Galler, Claudia Nunes Duarte Dos Santos","doi":"10.1007/82_2025_289","DOIUrl":"https://doi.org/10.1007/82_2025_289","url":null,"abstract":"<p><p>To write about dengue retrospective epidemiology is a challenging subject because until laboratory diagnosis tests were developed to confirm human infections by dengue virus (DENV) between 1940 and 1950, all reports about disease or epidemics referred to a generic \"dengue/break bone fever/contagious fever/bilious remitting fever.\" These nomenclatures employed in past times had perspectives based on medical reports, letters and diaries of people living in the affected areas at the time, and local newspaper reports. As Packard (Bull Hist Med 90(2):193-221) highlighted, the difficulty of using historical sources and \"the ambiguous nature\" of eighteenth-century disease categories turns the analysis puzzling. Nevertheless, if judiciously used, it can illuminate the history of dengue epidemics over time.In this chapter, we will focus on three periods that were pivotal to shaping our current understanding of dengue disease and epidemiology: (1) First reports of a dengue-like disease and the impact of the infection during the seventeenth and eighteenth centuries; (2) The impact of the II World War (II WW) on the spread of the DENV and its vector worldwide; and (3) The re-introduction of dengue in the Americas and the challenge of Public Health services to control the dramatic escalation of cases and the introduction of new serotypes/genotypes. It is worth mentioning that in the last years, South and Central America and Caribe account for more than 80% of dengue cases in the world (PAHO).</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-04-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143995009","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Using Passive Antibody Therapies in the Next Pandemic. 在下一次大流行中使用被动抗体疗法。
3区 医学
Current topics in microbiology and immunology Pub Date : 2024-12-19 DOI: 10.1007/82_2024_283
Nigel Paneth, Michael J Joyner, Arturo Casadevall
{"title":"Using Passive Antibody Therapies in the Next Pandemic.","authors":"Nigel Paneth, Michael J Joyner, Arturo Casadevall","doi":"10.1007/82_2024_283","DOIUrl":"https://doi.org/10.1007/82_2024_283","url":null,"abstract":"<p><p>The twenty-first century has witnessed seven human viral pandemics. Approximately once every three to four years over the past quarter-century, the world has experienced a new viral epidemic that expanded well beyond its original national borders to become a pandemic. The probability that another pandemic caused by a previously unknown agent will occur in the near future is thus very high and public health agencies must prioritize mechanisms for detecting their first signals. At the onset of these recent pandemics, no specific therapeutic agent was available for any of the newly emergent pathogens. However, convalescent plasma therapy can be available as soon as there are survivors and is likely to be effective if used early and in sufficient strength. But for the three forms of passive antibody-convalescent plasma, monoclonal antibodies, and hyperimmune globulins-to be available and effective in a pandemic situation, careful strategic planning will be necessary. In the pre-pandemic period, we must reinforce the capacities of blood banks and plasma fractionating companies in the production and storage of their products; ensure that outpatient settings can provide intravenous products; educate providers in the proper use of plasma; and create a research infrastructure to examine the effectiveness of passive antibody products. Once a pandemic is underway, regulatory bodies should simplify the approval of research and emergency use protocols and develop treatment registries. Incentives for the rapid production of monoclonal antibodies and hyperimmune globulins will likely be required. A national resource to link providers with passive antibody products and national databases to monitor pandemic progress and pandemic treatment will permit the most effective allocation of pandemic-fighting resources. We cannot afford to wait until the next pandemic is upon us to respond. The time to strengthen clinical, research, and manufacturing infrastructure to permit us to be ready to confront the next new virulent pathogen is now.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142845990","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Safety Profile of COVID-19 Convalescent Plasma. COVID-19恢复期血浆的安全性
3区 医学
Current topics in microbiology and immunology Pub Date : 2024-12-19 DOI: 10.1007/82_2024_282
Michael J Joyner, Rickey E Carter, R Scott Wright, Jonathon W Senefeld
{"title":"The Safety Profile of COVID-19 Convalescent Plasma.","authors":"Michael J Joyner, Rickey E Carter, R Scott Wright, Jonathon W Senefeld","doi":"10.1007/82_2024_282","DOIUrl":"https://doi.org/10.1007/82_2024_282","url":null,"abstract":"<p><p>Despite concerns about potential side effects, based both on historical experience with plasma products and more recent concerns about contemporary use of plasma, COVID-19 convalescent plasma has been shown to be a very safe product. Research early in the COVID-19 pandemic documented-among the very large population of convalescent plasma recipients in the US Convalescent Plasma Study component of the FDA-authorized Expanded Access Program-that the overall risk profile was no different than that seen for fresh frozen plasma, a product used routinely in medical practice. The safety of CCP was further demonstrated using real-world evidence, pragmatic trials, and formal randomized trials. The rates of all serious adverse events were very low, an especially impressive finding in light of the fact that nearly all safety data came from the use of COVID-19 convalescent plasma in patients who were hospitalized, were older, and/or had significant co-morbid cardiopulmonary and metabolic disorders. The well-known complications of blood and plasma transfusions-transfusion-associated circulatory overload and transfusion-related acute lung injury-were found with no higher incidence than with standard use of blood and plasma, nor was there evidence for antibody-dependent enhancement or increased incidence of thromboembolic events. The comprehensive safety profile derived from studies enrolling hundreds of thousands of recipients of COVID-19 convalescent plasma across the world should allay safety fears about the rapid deployment of convalescent plasma in future pandemics.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142846056","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Importance of Antibody Titer Determination to the Effective Use of Convalescent Plasma. 抗体效价测定对康复者血浆有效利用的重要性。
3区 医学
Current topics in microbiology and immunology Pub Date : 2024-12-07 DOI: 10.1007/82_2024_281
Peter W Marks
{"title":"The Importance of Antibody Titer Determination to the Effective Use of Convalescent Plasma.","authors":"Peter W Marks","doi":"10.1007/82_2024_281","DOIUrl":"https://doi.org/10.1007/82_2024_281","url":null,"abstract":"<p><p>Convalescent Plasma (CP) has been used prophylactically and therapeutically over the past century to address a variety of infectious threats. Two tenets of the use of CP were clear from prior experience in the setting of other infectious outbreaks: (1) best results are obtained when CP is given early in the course of the disease, and (2) plasma containing high-titer neutralizing capacity is necessary to achieve optimal results. The magnitude of the COVID-19 pandemic along with the initial lack of effective therapeutic alternatives, combined with the relative safety of the approach of administration of CP, led to the initiation of an expanded access program (EAP) that ultimately provided CP to tens of thousands of individuals. When the program was initiated, no high-throughput assay was available for the determination of antibody titers, so antibody positive units were administered without regard to titer. With foresight regarding the need to ultimately determine such titers, samples from the CP units administered were retained and titers were determined retrospectively. An automated live-virus neutralization assay was ultimately selected for this purpose based on an evaluation of its accuracy and precision. Ultimately, an analysis performed in 13,794 individuals from the EAP for which clinical outcomes were known following the administration of single units of COVID-19 CP between the period of April and August 2020 indicated that higher titer COVID-19 CP was associated with a modest reduction in absolute mortality. The benefit observed was confined to individuals who were not intubated, and there was a trend toward a greater reduction in mortality using the highest SARS-CoV-2 neutralizing antibody-containing CP units. This experience during the COVID-19 pandemic is instructive for the future. To facilitate the production of CP that is likely to be most effective, high-throughput assays to determine neutralizing antibody titers need to be developed and implemented early during an outbreak to facilitate the identification and early administration of high-titer units.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142784467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19. COVID-19 之前多克隆抗体治疗细菌和病毒疾病的简史。
3区 医学
Current topics in microbiology and immunology Pub Date : 2024-08-30 DOI: 10.1007/82_2024_279
Nigel Paneth, Madison Walsh, Breanna Kornatowski, Arturo Casadevall
{"title":"A Brief History of Polyclonal Antibody Therapies Against Bacterial and Viral Diseases Before COVID-19.","authors":"Nigel Paneth, Madison Walsh, Breanna Kornatowski, Arturo Casadevall","doi":"10.1007/82_2024_279","DOIUrl":"10.1007/82_2024_279","url":null,"abstract":"<p><p>The use of the serum or plasma of patients or animals who have recovered from an infectious disease, or had been immunized with a relevant antigen, to treat or prevent the same infection in others began in the late 1880s when French and German scientists uncovered, one step at a time, several of the elements of the immune system's response to infection. A key finding was that the damage caused by some bacteria depends upon their secreted toxins which can be neutralized by biologic agents. Antitoxins to diphtheria and tetanus began to be manufactured in large animals in France, Germany, and the US in the 1890s and were soon being used worldwide. The impact of diphtheria antitoxin on childhood mortality was profound. Shortly after the development of antitoxins, convalescent serum began to be used for its anti-bactericidal properties thus addressing serious infections caused by non-toxin-producing organisms. The effectiveness of antitoxins and antisera was demonstrated by examining mortality rates in hospitals before and after the introduction of antitoxins, by comparisons of treated and untreated patients, by comparing early and late treatment and dosage, by examining vital data mortality trends, and by several randomized and alternate assignment trials. Antitoxins continue to have a role in the rare cases of diphtheria and other conditions largely eradicated by immunization, but serum therapy nearly disappeared from the medical armamentarium with the development of antibiotics in the 1940s. Inasmuch as new human pathogens are now emerging with unprecedented regularity as seen in the recent COVID-19 pandemic, and because specific therapies are unlikely to be available for them, plasma-based antibody therapies are likely to again carve out a niche in infectious disease control.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142105160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Alterations of the AKT Pathway in Sporadic Human Tumors, Inherited Susceptibility to Cancer, and Overgrowth Syndromes. 散发性人类肿瘤、遗传性癌症易感性和过度生长综合征中 AKT 通路的改变
3区 医学
Current topics in microbiology and immunology Pub Date : 2024-08-28 DOI: 10.1007/82_2024_278
Craig W Menges, Dalal Hassan, Mitchell Cheung, Alfonso Bellacosa, Joseph R Testa
{"title":"Alterations of the AKT Pathway in Sporadic Human Tumors, Inherited Susceptibility to Cancer, and Overgrowth Syndromes.","authors":"Craig W Menges, Dalal Hassan, Mitchell Cheung, Alfonso Bellacosa, Joseph R Testa","doi":"10.1007/82_2024_278","DOIUrl":"https://doi.org/10.1007/82_2024_278","url":null,"abstract":"<p><p>The AKT kinases are critical signaling molecules that regulate cellular physiology upon the activation of tyrosine kinase receptors and phosphatidylinositol 3-kinases (PI3K). AKT kinases govern many cellular processes considered hallmarks of cancer, including cell proliferation and survival, cell size, tumor invasion, metastasis, and angiogenesis. AKT signaling is regulated by multiple tumor suppressors and oncogenic proteins whose loss or activation, respectively, leads to dysregulation of this pathway, thereby contributing to oncogenesis. Herein, we review the enormous body of literature documenting how the AKT pathway becomes hyperactivated in sporadic human tumors and various hereditary cancer syndromes. We also discuss the role of activating mutations of AKT pathway genes in various chimeric overgrowth disorders, including Proteus syndrome, hypoglycemia with hypertrophy, CLOVES and SOLAMEN syndromes, and hemimegalencephaly.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence for the Efficacy of COVID-19 Convalescent Plasma. 证明 COVID-19 新陈代谢血浆功效的证据
3区 医学
Current topics in microbiology and immunology Pub Date : 2024-08-28 DOI: 10.1007/82_2024_280
Stephen A Klassen, Jonathon W Senefeld
{"title":"Evidence for the Efficacy of COVID-19 Convalescent Plasma.","authors":"Stephen A Klassen, Jonathon W Senefeld","doi":"10.1007/82_2024_280","DOIUrl":"https://doi.org/10.1007/82_2024_280","url":null,"abstract":"<p><p>During the global health emergency caused by the coronavirus disease 2019 (COVID-19), evidence relating to the efficacy of convalescent plasma therapy-evidence critically needed for both public policy and clinical practice-came from multiple levels of the epistemic hierarchy. The challenges of conducting clinical research during a pandemic, combined with the biological complexities of convalescent plasma treatment, required the use of observational data to fully assess the impact of convalescent plasma therapy on COVID symptomatology, hospitalization rates, and mortality rates. Observational studies showing the mortality benefits of convalescent plasma emerged early during the COVID-19 pandemic from multiple continents and were substantiated by real-time pragmatic meta-analyses. Although many randomized clinical trials (RCTs) were initiated at the onset of the pandemic and were designed to provide high-quality evidence, the relative inflexibility in the design of clinical trials meant that findings generally lagged behind other forms of emerging information and ultimately provided inconsistent results on the efficacy of COVID-19 convalescent plasma. In the pandemic framework, it is necessary to emphasize more flexible analytic strategies in clinical trials, including secondary, subgroup, and exploratory analyses. We conclude that in totality, observational studies and clinical trials taken together provide strong evidence of a mortality benefit conferred by COVID-19 convalescent plasma, while acknowledging that some randomized clinical trials examined suboptimal uses of convalescent plasma.</p>","PeriodicalId":11102,"journal":{"name":"Current topics in microbiology and immunology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142079585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信